

Masaru Enomoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4324494/publications.pdf>

Version: 2024-02-01

170
papers

3,385
citations

147566

31
h-index

197535

49
g-index

174
all docs

174
docs citations

174
times ranked

4449
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. <i>Gut</i> , 2012, 61, 1600-1609.	6.1	212
2	Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. <i>Journal of Gastroenterology</i> , 2011, 46, 556-564.	2.3	135
3	Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. <i>Hepatology Research</i> , 2013, 43, 1264-1275.	1.8	91
4	Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2011, 46, 350-358.	2.3	83
5	Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. <i>Liver International</i> , 2007, 27, 186-191.	1.9	78
6	Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray. <i>PLoS ONE</i> , 2014, 9, e106314.	1.1	74
7	Induction of microRNA-214-5p in human and rodent liver fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, 12.	3.4	73
8	Alteration of Gene Expression in Human Hepatocellular Carcinoma with Integrated Hepatitis B Virus DNA. <i>Clinical Cancer Research</i> , 2005, 11, 5821-5826.	3.2	72
9	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.2	72
10	Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. <i>Hepatology</i> , 2020, 71, 1910-1922.	3.6	70
11	Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1039-1052.	3.7	70
12	Does GBV-C cause fulminant hepatitis in Japan?. <i>Lancet</i> , The, 1996, 347, 908.	6.3	65
13	Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. <i>Journal of Medical Virology</i> , 2005, 75, 235-239.	2.5	63
14	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 473-485.	1.8	62
15	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	1.9	58
16	Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease. <i>Hepatology Communications</i> , 2020, 4, 284-297.	2.0	53
17	Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. <i>Hepatology Research</i> , 2010, 40, 853-861.	1.8	51
18	A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: Validation using prognostic markers for pre-liver transplant status. <i>Liver Transplantation</i> , 2009, 15, 790-797.	1.3	50

#	ARTICLE	IF	CITATIONS
19	Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation, 2016, 2016, 1-11.	1.4	49
20	Hepatitis B virus infection and alcohol consumption. World Journal of Gastroenterology, 2017, 23, 2651.	1.4	49
21	A Clinical Quantitative Evaluation of Hepatobiliary Transport of [¹¹ C]Dehydropravastatin in Humans Using Positron Emission Tomography. Drug Metabolism and Disposition, 2018, 46, 719-728.	1.7	49
22	Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. Journal of Viral Hepatitis, 2010, 17, 123-129.	1.0	48
23	Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver. Laboratory Investigation, 2014, 94, 192-207.	1.7	48
24	Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. Scientific Reports, 2020, 10, 3392.	1.6	46
25	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. Journal of Infectious Diseases, 2021, 224, 1890-1899.	1.9	40
26	Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatology Research, 2003, 25, 312-318.	1.8	39
27	Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. Journal of Gastroenterology, 2009, 44, 608-614.	2.3	38
28	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatology International, 2020, 14, 1023-1033.	1.9	38
29	Applicability of BARD score to Japanese patients with NAFLD. Gut, 2009, 58, 1566-1567.	6.1	37
30	Hepatitis B virus genotypes and response to antiviral therapy. Clinical Laboratory, 2006, 52, 43-7.	0.2	37
31	Nutritional status in relation to lifestyle in patients with compensated viral cirrhosis. World Journal of Gastroenterology, 2012, 18, 5759.	1.4	32
32	Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. Journal of Medical Virology, 2009, 81, 1009-1014.	2.5	31
33	Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. Journal of Viral Hepatitis, 2018, 25, 608-611.	1.0	30
34	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clinical Infectious Diseases, 2020, 71, 2840-2848.	2.9	30
35	Expression of Connective Tissue Growth Factor in the Human Liver with Idiopathic Portal Hypertension. Molecular Medicine, 2007, 13, 240-245.	1.9	29
36	Entecavir to Treat Hepatitis B-Associated Cryoglobulinemic Vasculitis. Annals of Internal Medicine, 2008, 149, 912.	2.0	29

#	ARTICLE	IF	CITATIONS
37	Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 11912.	1.6	28
38	Characteristics of patients with hepatitis C virus with and without GB virus C/Hepatitis G virus Co-infection and efficacy of interferon alfa. <i>Hepatology</i> , 1998, 27, 1388-1393.	3.6	27
39	Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. <i>Journal of Medical Virology</i> , 2003, 69, 475-481.	2.5	27
40	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	1.9	27
41	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	2.4	27
42	TGF- β 1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 73, 882-895.	1.8	24
43	Effect of Mosapride Citrate on Gastric Emptying in Interferon-Induced Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1510-1516.	1.1	23
44	Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1715-1721.	1.4	23
45	Anti-fibrotic treatments for chronic liver diseases: The present and the future. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 413-424.	4.5	23
46	Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. <i>Journal of Medical Virology</i> , 2007, 79, 1664-1670.	2.5	22
47	Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1391-1400.	1.6	22
48	Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 904-909.	1.4	21
49	Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1095-1104.	1.4	21
50	Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014, 20, 12031.	1.4	21
51	Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan) T_j ETQq1 1 0.784314 rgBT /Over 125-133.	1.8	20
52	Entecavir and interferon- β sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2013, 48, 397-404.	2.3	20
53	Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. <i>Hepatology Research</i> , 2019, 49, 1365-1373.	1.8	20
54	Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. <i>Biomedicines</i> , 2019, 7, 87.	1.4	20

#	ARTICLE	IF	CITATIONS
55	Prevalence of GBV-C and hepatitis G virus variants in patients with fulminant hepatic failure in Japan. <i>Journal of Hepatology</i> , 1997, 27, 966-972.	1.8	19
56	Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection. <i>Liver International</i> , 2009, 29, 126-132.	1.9	19
57	Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. <i>Journal of Gastroenterology</i> , 2013, 48, 999-1005.	2.3	19
58	Two cases of hepatocellular adenomatosis treated with transcatheter arterial embolization. <i>Hepatology International</i> , 2009, 3, 416-420.	1.9	18
59	Putting "sticky notes" on the electronic medical record to promote intra-hospital referral of hepatitis B and C virus-positive patients to hepatology specialists: an exploratory study. <i>BMC Infectious Diseases</i> , 2016, 16, 410.	1.3	18
60	Accessory spleen in the pelvis diagnosed by Tc-99m phytate scintigraphy. <i>Annals of Nuclear Medicine</i> , 2001, 15, 263-265.	1.2	17
61	TT virus infection in patients with chronic liver disease of unknown etiology. <i>Journal of Medical Virology</i> , 2000, 62, 392-398.	2.5	16
62	A case of sclerosing cholangitis with autoimmune pancreatitis evaluated by FDG-PET. <i>Annals of Nuclear Medicine</i> , 2007, 21, 223-228.	1.2	16
63	Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2011, 41, 897-903.	1.8	16
64	Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy. <i>Hepatology</i> , 2001, 33, 241-247.	3.6	15
65	MicroRNA expression in hepatocellular carcinoma after the eradication of chronic hepatitis virus C infection using interferon therapy. <i>Hepatology Research</i> , 2016, 46, E26-35.	1.8	15
66	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. <i>Journal of Gastroenterology</i> , 2018, 53, 247-257.	2.3	15
67	Interferon- α plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial. <i>Gut</i> , 2006, 55, 139-140.	6.1	14
68	Positioning of ^{18}F -fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1722-1727.	1.4	14
69	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	1.9	14
70	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. <i>Scientific Reports</i> , 2021, 11, 13844.	1.6	14
71	Prevalence of TT virus in patients with fulminant hepatic failure in Japan. <i>Journal of Gastroenterology</i> , 1999, 34, 589.	2.3	13
72	Adefovir Dipivoxil to Prevent Exacerbation of Lamivudine-resistant Hepatitis B Infection during Chemotherapy for Non-Hodgkin's Lymphoma. <i>American Journal of Gastroenterology</i> , 2004, 99, 1619-1620.	0.2	13

#	ARTICLE	IF	CITATIONS
73	Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon- α 2b and ribavirin therapy in patients with genotype 1 and high viral loads. <i>Journal of Medical Virology</i> , 2005, 77, 77-82.	2.5	13
74	Plummer's Vinson syndrome successfully treated by endoscopic dilatation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 2348-2351.	1.4	13
75	Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon- α and ribavirin therapy, and efficacy of retreatment. <i>Hepatology Research</i> , 2012, 42, 1157-1167.	1.8	13
76	Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated interferon and ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 201-207.	1.4	13
77	Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas. <i>Oncology</i> , 2021, 99, 186-191.	0.9	13
78	Effects of ribavirin combined with interferon-alpha2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. <i>Journal of Viral Hepatitis</i> , 2004, 11, 448-454.	1.0	12
79	Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. <i>Liver International</i> , 2007, 27, 95-100.	1.9	12
80	A case of primary small cell carcinoma of the liver that was treated with chemotherapy. <i>Hepatology International</i> , 2008, 2, 500-4.	1.9	12
81	A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2013, 52, 1589-1592.	0.3	12
82	Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. <i>Cancers</i> , 2020, 12, 2045.	1.7	12
83	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. <i>American Journal of Gastroenterology</i> , 2021, 116, 1264-1273.	0.2	12
84	Codeine Phosphate-Induced Hypersensitivity Syndrome. <i>Annals of Pharmacotherapy</i> , 2004, 38, 799-802.	0.9	11
85	The presence of multiple NS5A RAS mutations is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. <i>Journal of Viral Hepatitis</i> , 2018, 25, 535-542.	1.0	11
86	Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication. <i>PLoS ONE</i> , 2018, 13, e0194163.	1.1	11
87	Does ascorbic acid prevent retinopathy during interferon therapy in patients with chronic hepatitis C?. <i>Journal of Gastroenterology</i> , 2001, 36, 486-491.	2.3	10
88	Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. <i>Hepatology Research</i> , 2012, 42, 549-557.	1.8	10
89	Development of novel hepatitis B virus capsid inhibitor using in silico screening. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 1165-1175.	1.0	10
90	Discovering novel direct acting antiviral agents for HBV using in silico screening. <i>Biochemical and Biophysical Research Communications</i> , 2015, 456, 20-28.	1.0	10

#	ARTICLE	IF	CITATIONS
91	Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1495-1502.	1.4	10
92	Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. <i>Journal of Medical Virology</i> , 2019, 91, 1295-1300.	2.5	10
93	Establishing Efficient Systems through Electronic Medical Records to Promote Intra-hospital Referrals of Hepatitis Virus Carriers to Hepatology Specialists: A Multicenter Questionnaire-based Survey of 1,281 Healthcare Professionals. <i>Internal Medicine</i> , 2021, 60, 337-343.	0.3	10
94	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Liver International</i> , 2022, 42, 59-68.	1.9	10
95	Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment. <i>American Journal of Gastroenterology</i> , 2002, 97, 420-426.	0.2	9
96	Sildenafil-Induced Severe Cholestatic Hepatotoxicity. <i>American Journal of Gastroenterology</i> , 2009, 104, 254-255.	0.2	9
97	Promotion of intra-hospital referral of hepatitis B and C virus carriers to hepatology specialists by electronic medical record-based alert system: a case study at a university hospital. <i>Acta Hepatologica Japonica</i> , 2016, 57, 7-16.	0.0	9
98	Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination. <i>Annals of Hepatology</i> , 2017, 16, 734-741.	0.6	9
99	Association between <i>HLA-DQA1/DRB1</i> polymorphism and development of hepatocellular carcinoma during entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 937-946.	1.4	9
100	GB virus C and TT virus infections in Japanese patients with autoimmune hepatitis. <i>Journal of Medical Virology</i> , 2002, 66, 258-262.	2.5	8
101	Lamivudine and IFN- β Sequential Therapy in HBe Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 201-208.	0.5	8
102	Emerging Antiviral Drugs for Hepatitis C Virus. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 179-184.	0.4	8
103	Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b. <i>Hepatology Research</i> , 2016, 46, 1311-1320.	1.8	8
104	Development of a novel anti-hepatitis B virus agent via Sp1. <i>Scientific Reports</i> , 2020, 10, 47.	1.6	8
105	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 977-989.	2.3	8
106	Benefits of artificially induced pleural effusion and/or ascites for percutaneous radiofrequency ablation of hepatocellular carcinoma located on the liver surface and in the hepatic dome. <i>Hepato-Gastroenterology</i> , 2012, 59, 546-50.	0.5	8
107	Dynamics of Hepatitis C Virus Monitored by Real-Time Quantitative Polymerase Chain Reaction During First 2 Weeks of IFN- β Treatment Are Predictive of Long-Term Therapeutic Response. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 389-395.	0.5	7
108	Changes in hypervariable region 1 in patients with chronic hepatitis C of genotype 1b with biochemical response to interferon. <i>Hepatology Research</i> , 2002, 23, 237-250.	1.8	7

#	ARTICLE	IF	CITATIONS
109	Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. <i>Hepatology Research</i> , 2008, 38, 954-959.	1.8	7
110	Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals. <i>Annals of Internal Medicine</i> , 2018, 168, 678-680.	2.0	7
111	Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 355-360.	0.4	7
112	Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein. <i>Gut</i> , 2021, 70, 1199-1201.	6.1	7
113	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	1.9	7
114	Effect of Caffeine-Containing Beverage Consumption on Serum Alanine Aminotransferase Levels in Patients with Chronic Hepatitis C Virus Infection: A Hospital-Based Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83382.	1.1	6
115	Changes in plasma interleukin-8 and tumor necrosis factor- α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 857-864.	1.1	6
116	Combination of Entecavir or Tenofovir with Pegylated Interferon- α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1456.	1.8	6
117	Accurate Prediction of Response to Interferon Therapy by Repeated Measurement of Hepatitis C Virus Core Protein in Patients with Chronic Hepatitis C. <i>Intervirology</i> , 2002, 45, 105-110.	1.2	5
118	Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon- α 2 in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 613-620.	0.5	5
119	Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed. <i>International Journal of Molecular Sciences</i> , 2017, 18, 962.	1.8	5
120	Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. <i>Annals of Hepatology</i> , 2020, 19, 367-372.	0.6	5
121	Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 217-224.	1.4	5
122	Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation. <i>Journal of Medical Virology</i> , 2021, 93, 3679-3687.	2.5	5
123	A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2021, 16, e0257166.	1.1	5
124	Lenvatinib-Induced Tumor-Related Hemorrhage in Patients With Unresectable Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2021, 116, 631-631.	0.2	5
125	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0263844.	1.1	5
126	Association of HLA Alleles with Response (Especially Biochemical Response) to Interferon Therapy in Japanese Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2003, 23, 135-141.	0.5	4

#	ARTICLE	IF	CITATIONS
127	Alcohol abuse as an etiologic factor for hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2005, 31, 73-78.	1.8	4
128	Favorable factors for re-treatment with pegylated interferon λ 2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. <i>Hepatology Research</i> , 2011, 41, 1169-1177.	1.8	4
129	Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy. <i>Annals of Hepatology</i> , 2015, 14, 28-35.	0.6	4
130	Sequential therapy involving an early switch from entecavir to pegylated interferon λ 1 in Japanese patients with chronic hepatitis B. <i>Hepatology Research</i> , 2018, 48, 459-468.	1.8	4
131	The Moral of Hepatic Fibrosis: Don't Always Believe Noninvasive Fibrosis Measurements. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1293-1295.	1.1	4
132	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	2.4	4
133	Platelet-associated IgG for the diagnosis of immune thrombocytopenic purpura during peginterferon λ 2a and ribavirin treatment for chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1314-1315.	1.9	3
134	High prevalence of hepatitis C virus infection in Airin district, Osaka, Japan: A hospital-based study of 1162 patients. <i>Hepatology Research</i> , 2011, 41, 731-737.	1.8	3
135	Combination therapy of natural human interferon β and ribavirin for chronic hepatitis C patients with injection drug use. <i>Hepatology Research</i> , 2013, 43, 1013-1019.	1.8	3
136	Interferon λ 1/2 for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents. <i>Hepatology Research</i> , 2014, 44, 371-376.	1.8	3
137	Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 598-602.	0.4	3
138	High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. <i>JGH Open</i> , 2020, 4, 964-969.	0.7	3
139	Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients—Relationship to smoking and alcohol. <i>JGH Open</i> , 2020, 4, 867-875.	0.7	3
140	Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4517.	1.8	3
141	Present status of hepatitis medical care coordinators in regional core centers in Japan. <i>Acta Hepatologica Japonica</i> , 2021, 62, 96-98.	0.0	3
142	Successful Transcatheter Arterial Embolization for Hemothorax from a Spontaneous Rupture of Hepatocellular Carcinoma Metastasis to the Chest Wall in an Elderly Patient. <i>Internal Medicine</i> , 2021, 60, 2223-2228.	0.3	3
143	Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment. <i>Scientific Reports</i> , 2022, 12, 105.	1.6	3
144	Meshwork pattern is an important risk factor for development of hepatocellular carcinoma in patients with HBV-related chronic hepatitis and cirrhosis. <i>Hepatology Research</i> , 2003, 25, 166-173.	1.8	2

#	ARTICLE	IF	CITATIONS
145	Could Trastuzumab Suppress Hepatitis C Virus in a Patient With Chronic Hepatitis and Breast Cancer?. <i>American Journal of Gastroenterology</i> , 2011, 106, 1865-1866.	0.2	2
146	A pregnant woman with acute hepatitis B in whom vertical transmission was prevented by tenofovir disoproxil fumarate. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 173-176.	0.4	2
147	Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 860-866.	0.4	2
148	The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B. <i>Internal Medicine</i> , 2020, 59, 205-210.	0.3	2
149	Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed. <i>Internal Medicine</i> , 2021, 60, 3441-3445.	0.3	2
150	Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2021, 60, 545-552.	0.3	2
151	Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. <i>JGH Open</i> , 2021, 5, 801-808.	0.7	2
152	Direct-Acting Antivirals Reduce the Risk of Tumor Progression of Hepatocellular Carcinoma after Curative Treatment. <i>Journal of Viral Hepatitis</i> , 2021, , .	1.0	2
153	TRENDS IN THE CAUSES AND OUTCOME OF LIVER CIRRHOSIS DIAGNOSED BY LAPAROSCOPY IN OSAKA, JAPAN DURING THE PAST THREE DECADES. <i>Digestive Endoscopy</i> , 2001, 13, 13-16.	1.3	1
154	SEN viruses and treatment response in chronic hepatitis C virus. <i>Lancet, The</i> , 2002, 359, 1780-1781.	6.3	1
155	Laparoscopic observation of 2 cases of nodular regenerative hyperplasia of the liver. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 171-173.	0.5	1
156	Anti-hepatitis B virus therapy: To stop, or not to stop: Has the question been solved?. <i>Hepatology Research</i> , 2012, 42, 946-947.	1.8	1
157	Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for "middle"? <i>Journal of Gastroenterology</i> , 2013, 48, 555-556.	2.3	1
158	Adjuvant epoetin- α with peginterferon- α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2. <i>Hepatology Research</i> , 2014, 44, E290-6.	1.8	1
159	A case of hepatitis C virus-associated mixed cryoglobulinemic vasculitis treated with daclatasvir and asunaprevir. <i>Acta Hepatologica Japonica</i> , 2016, 57, 328-333.	0.0	1
160	Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?. <i>Gastroenterology</i> , 2017, 153, 327-328.	0.6	1
161	A case series of five patients with hepatic sarcoidosis diagnosed by liver biopsy. <i>Acta Hepatologica Japonica</i> , 2019, 60, 405-413.	0.0	1
162	Perirectal portal scintigraphy as an alternative measure of hepatic venous pressure gradient in chronic liver disease: A preliminary report. <i>Clinical Physiology and Functional Imaging</i> , 2021, 41, 334-341.	0.5	1

#	ARTICLE	IF	CITATIONS
163	I shall be released (from infinite HBV nucleos(t)ide analog therapy): Japanese experience. Journal of Hepatology, 2021, 75, 1496-1497.	1.8	1
164	Infection route of hepatitis C patients treated with direct-acting antivirals -To evaluate the risk of reinfection-. Acta Hepatologica Japonica, 2017, 58, 435-440.	0.0	0
165	Last crusade against HCV: Direct-acting antiviral treatment for marginalized populations. Journal of Viral Hepatitis, 2019, 26, 1501-1501.	1.0	0
166	Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus. Clinical Journal of Gastroenterology, 2019, 12, 213-217.	0.4	0
167	A case of ectopic hepatocellular carcinoma originating from the retroperitoneum. Acta Hepatologica Japonica, 2020, 61, 597-606.	0.0	0
168	Real-time PCR assays for hepatitis C virus RNA (genotype 1) is useful for evaluating virological response to the treatment with peginterferon-alpha2b and ribavirin. Osaka City Medical Journal, 2013, 59, 79-89.	0.4	0
169	Hepatocellular Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?. Hepatology Communications, 2022, 6, 445-447.	2.0	0
170	Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study. BMC Gastroenterology, 2021, 21, 489.	0.8	0